anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aims to investigate changes in gastric motility (including gastric accommodation), nutrient volume tolerance, gastric emptying and gastrointestinal hormones in healthy volunteers after an acute intake of a combination of peppermint oil and caraway oil, compared to placebo. In addition, the effect of a combination of peppermint oil and caraway oil on appetite-related sensations and upper gastrointestinal symptoms will be assessed. These outcomes will be studied on 2 study days. On study day 1, gastric emptying rate will be assessed using a 13C breath test 30 minutes after intake of study medication. This test is followed by an intragastric pressure (IGP) measurement during which 350 mL of a nutrient drink will be intragastrically infused 30 minutes after intake of study medication. On the second study day, IGP will be measured in fasted state for 4 hours after intake of study medication. Hereafter, a second dose of study medication will be administered. Thirty minutes later, a nutrient drink will be infused until the participant is fully satiated. Appetite-related sensations and gastrointestinal symptoms will be rated during IGP measurements on a 100mm VAS. Blood samples will be collected to assess peptide hormone levels.
Electrophysiological studies of congenitally deaf children and adults have reported atypical visual evoked potentials (VEPs) which have been associated with both behavioral enhancements of visual attention as well as poorer performance and outcomes in tests of spoken language speech processing. This pattern has often been interpreted as a maladaptive consequence of early auditory deprivation, whereby a remapping of auditory cortex by the visual system ultimately reduces resources necessary for optimal rehabilitative outcomes of spoken language acquisition and use. Making use of a novel electrophysiological paradigm, we compare VEPs in children with severe to profound congenital deafness who received a cochlear implant(s) prior to 31 months (n = 28) and typically developing age matched controls (n = 28). We observe amplitude enhancements and in some cases latency differences in occipitally expressed P1 and N1 VEP components in CI-using children as well as an early frontal negativity, N1a. We relate these findings to developmental factors such as chronological age and spoken language understanding. We further evaluate whether VEPs are additionally modulated by auditory stimulation. Collectively, these data provide a means to examine the extent to which atypical VEPs are consistent with prior accounts of maladaptive cross-modal plasticity. Our results support a view that VEP changes reflect alterations to visual-sensory attention and saliency mechanisms rather than a re-mapping of auditory cortex. The present data suggests that early auditory deprivation may have temporally prolonged effects on visual system processing even after activation and use of cochlear implant.
FIELD: medicine. SUBSTANCE: invention relates to the novel immunomodulating drug "Izofon" showing an antimycobacterial activity, method of its preparing and using. Method involves the interaction of equimolar amount of 6-methyluracil-5-sulfochloride and isonicotinic acid hydrazide in absolute acetonitrile at 81 C, filtration, precipitate dissolving in hot water, filtration, addition of NH 4 OH to filtrate up to pH 7, precipitate preparing and its crystallization from dimethylformamide (DMFA). Obtained substance is N-(6-methyl-2,4-dioxo-1,2,3,4-tetrahydro- -5-pyrimidinesulfone)-N-isonicotinoylhydrazide hydrate that shows an antimycobacterial activity used orally and by parenteral route. The developed new immunomodulating agent showing an antimycobacterial activity can be used in secondary immunodeficiency and mycobacteriosis also. EFFECT: new agent indicated above, enhanced an antimycobacterial activity. 4 cl, 3 tbl, 5 ex
PURPOSE:A cosmetic base containing oil and a powder base is pressed in an inner dish which has perforations on its bottom, then the pressed base is impregnated with oil cosmetic to give a pressed cosmetic which has high oil content and good appearance. CONSTITUTION:A mixture of an oil such as olive oil or fluid paraffin with a powder base such as titanium oxide, talc or mica is pressed into a form in an inner dish which has a plurality of perforation on the bottom. Then, 100pts.wt. of the pressed cosmetic base is impregnated with less than 30pts.wt. of liquid oil such as fluid paraffin, squallan, or silicone oil by dripping or atomizing. EFFECT:It is free from greasy feeling and gives appropriate moistness and good adhesion to skins. Further, it is produced without lowering in workability.
PURPOSE: A water extract PF-01, PF-02 AND PF-03 obtained from extraction of an egg with chloroform/methanol after removal of an eggshell from the egg and then removal of a lipid-soluble material therefrom is provided. The extract can be effectively used in treatment of circulatory organ-related diseases caused by thrombogenesis such as hyperlipidemia, myocardial infarction, cerebral thrombosis, hypertension, etc. because it has antithrombin activity such as inhibition of platelet aggregation, retardation of a blood coagulation time and a production increase of cAMP and cGMP. CONSTITUTION: An egg is extracted in chloroform/methanol after removing an eggshell from the egg. An upper layer thereof is dried. The obtained dried powder is extracted in chloroform/water. And then a water layer thereof is removed therefrom to produce a water extract PF-01. A lipid-soluble material such as phospholipid and cholesterol is removed from the PF-01, and extracted with chloroform/methanol. And then a water layer is filtered therefrom to produce a water extract PF-02 and PF-03.
A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.
PROBLEM TO BE SOLVED: To obtain the subject composition stable in the form of a gel, capable of making a wet feeling without a greasy feeling remain on skin after rinsing and useful as a cleaning agent by including a surface-active ingredient, an oil, a gelling agent and a nonionic emulsifying agent. SOLUTION: This gelled composition comprises (A) a surface-active ingredient composed of at least one kind of ionic surfactant (preferably an amphoteric surfactant or the like), (B) an oil (preferably a hydrocarbon oil or the like), (C) a gelling agent and (D) a nonionic emulsifying agent. The composition is preferably composed of the component A in an amount of 10-20 wt.%, the component B in an amount of 50-90 wt.%, the component C in an amount of 3-10 wt.% and the component D in an amount of 2.5-20 wt.% based on the whole weight thereof. Besides, the component C is mixed with the component D and the component A is added to the obtained mixture. Furthermore, the component B is added to obtain the composition. Thereby, the effective and nonirritant composition for cleaning can be expected.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

### Advanced Renal Disease

No information is available from controlled clinical studies regarding the use of ketoprofen immediate-release capsules or ketoprofen extended-release capsules in patients with advanced renal disease. Therefore, treatment with ketoprofen immediate-release capsules or ketoprofen extended-release capsules is not recommended in these patients with advanced renal disease. If ketoprofen immediate-release capsules or ketoprofen extended-release capsules therapy must be initiated, close monitoring of the patient's renal function is advisable.
Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
Our overall goal is to discover and validate diagnostic and prognostic biomarkers for musculoskeletal high-impact chronic pain. Chronic pain represents a public health crisis that affects 50-100 million Americans and costs over $500 billion dollars annually. Chronic musculoskeletal pain conditions comprise 70-80% of all chronic pain. The highest-need and most impacted patients are those with high-impact chronic pain (affecting \~20 million Americans), or pain associated with substantially restricted work, social, and self-care activities for six or more months. Chronic pain-and high-impact chronic pain in particular-is often treated with prescription opioids, and is linked to opioid-use disorder. Multidisciplinary chronic pain treatments show incomplete recovery at the population level. However, subgroups of individuals completely respond, do not change, or even worsen following pain management. Thus, robust and validated diagnostic and prognostic biomarkers are needed to identify those with high-impact chronic pain and determine the trajectory of outcome (i.e., recovery versus persistence), respectively. Such biomarkers are essential to develop safer, more effective patient-specific treatment strategies, particularly for those who are refractory to current treatment options.

Many factors have been shown to be (1) diagnostic for the severity and impact of chronic pain or (2) prognostic of the trajectory of chronic pain, including those that are related to the central nervous system (CNS; structure, function), psychosocial (e.g., anxiety, catastrophizing, social isolation), sensory (e.g., temporal summation, conditioned pain modulation),1functional (e.g., accelerometry), multiomic (e.g., immune, microbiome), and demographic. However, these studies are limited by (1) association rather than predictive validity; (2) small sample sizes; (3) homogenous populations limiting external validity; and (4) single modality factors. As chronic pain is a biopsychosocial condition, the investigator will need to measure broadly across these multiple dimensions; the most valuable insights will be gained by understanding not only individual pieces of data, but the relationships among them. Recognizing the critical need for rapid, valid, and clinically useful breakthroughs in signature discovery for risk- and treatment-stratification and novel therapeutic targets for chronic pain, as called for in the HEAL initiative, the investigator's aim is to discover reliable, validated diagnostic and prognostic biomarker signatures of musculoskeletal high-impact chronic pain by integrating CNS, multiomic, sensory, functional, psychosocial, and demographic domains.
PURPOSE:To obtain the titled extract having improved wound curing effect, skin adjusting and safety, etc., by defatting the dried rhizome of Angelica acutiloba Kitagawa with an organic solvent, extracting the defatted rhizome with water or hot water, and purifying the resultant extract with a synthetic adsorbent. CONSTITUTION:The dried rhizome of Angelica acutiloba Kitagawa is directly or in the form of fragments or powder is defatted or extracted with an organic solvent, e.g. n-hexane, benzene, toluene or xylene, to remove oil-soluble components, e.g. essential oil. The resultant defatted rhizome is then extracted with water or hot water. The resultant extract is purified with a synthetic resin adsorbent, e.g. adsorbent having a giant network structure and hydrophobic resin surface, and capable of adsorbing and separating an organic material in an aqueous solution; a copolymer consisting of styrene and divinylbenzene to afford the aimed extract of the Angelica acutiloba Kitagawa of high quality. The above-mentioned extract is light brown-white powder or viscous liquid.
The invention discloses a traditional Chinese medicine composition for treating haemorrhoids and a preparation method thereof, belonging to the field of haemorrhoids treatment by traditional Chinese medicines. The invention first disclosesthe traditional Chinese medicinecomposition for treating haemorrhoids. The traditional Chinese medicinecomposition comprises the following components:radix curcumae, pangolin, fructus chebulae, herba leonuri and indigo naturalis. The active pharmaceutical ingredients hive, flos sophorae immaturus and radix rubiae are added to the traditional Chinese medicine composition to realize better functions of cooling blood and stopping bleeding and dispelling stasis and relieving pain. The comparison result of clinical effects proves thatan obvious synergistic effect between the radix curcumae, pangolin, fructus chebulae, herba leonuri and indigo naturalis and the hive, flos sophorae immaturus and radix rubiae is realized, the cure rate of haemorrhoids reaches 94%, total effective rate is up to 100%, and the haemorrhoids does not relapse after healing. The traditional Chinese medicine composition disclosed by the invention has the advantages of reasonable compatibility, simple preparation method, convenience in use, no toxic or side effect, good treatment effect on haemorrhoids and good application prospect.
OBJECTIVE: To analyze the occurrence of osteolysis in total hip arthroplasty (THA) with highly cross-linked polyethylene prosthesis during a follow-up of more than 15 years.
METHODS: The clinical data of 84 patients (105 hips) treated with THA in the Affiliated Hospital of Kanazawa Medical University in Japan between June 2000 and April 2004 and met the selection criteria was retrospectively analyzed. There were 7 males and 77 females, aged from 41 to 75 years, with an average of 56.4 years. There were 94 hips with secondary hip osteoarthritis, 4 hips after pelvic osteotomy, 2 hips with primary hip osteoarthritis, 2 hips with traumatic hip osteoarthritis, 2 hips with osteonecrosis of the femoral head, and 1 hip with rheumatoid arthritis. According to Crowe classification, there were 79 hips of type Ⅰ, 19 hips of type Ⅱ, 6 hips of type Ⅲ, and 1 hip of type Ⅳ. The highly cross-linked polyethylene acetabular liner combined with a 26 mm zirconia femoral head were used in all patients. X-ray films were taken after operation to analyze the radiation transmission and osteolysis around the acetabular prosthesis. The vertical distance (the distance between the teardrop line at the lower edge of the pelvis and the perpendicular line of the hip rotation center), the horizontal distance (the horizontal distance between the hip rotation center and the interteardrop line and the vertical line at the lower edge of the teardrop), and the acetabular cup anteversion angle were measured at last follow-up. The acetabular and femoral osteolysis was analyzed by CT scan and three-dimensional multiplanar reconstruction (3D-MPR). Combined with X-ray film and CT results, osteolysis was evaluated according to the Narkbunnam score.
RESULTS: Deep vein thrombosis of lower limbs occurred in 2 cases. All patients were followed up 15-18 years, with an average of 15.9 years. One hip dislocation and 1 periprosthetic fracture occurred postoperatively, and no acetabular loosening or prosthetic lining ruptures occurred. Except for 1 patient who had a radiolucent line in the acetabulum after operation, the other 83 patients did not show any radiolucent line in the acetabulum or the femur. None of the patients underwent hip revision. X-ray films at last follow-up showed an acetabular cup anteversion angle of -10°-39°, with an average of 22°; a vertical distance of 3.5-47.1 mm, with an average of 24.6 mm; and a horizontal distance of 22.6-48.1 mm, with an average of 31.7 mm. There was no acetabular or femoral osteolysis in all patients on X-ray films and CT 3D-MPR images at last follow-up, and the Narkbunnam score was 0 in any region.
CONCLUSION: Highly cross-linked polyethylene prosthesis does not increase the risk of long-term complications such as osteolysis after THA.
Group IV: Similar to Group II, the canal was filled with 4 ml of the 2.5% NaOCl - 9% HEDP combined solution for 1 minute. The tip of the EA was placed 2 mm away from the WL, followed by 1 minute of sonic activation with the EA device (10,000 cycles per minute with a tip size 0.04/35).
Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
Oxygen-induced retinopathy (OIR) mouse model is widely used to study retinal neovascular diseases. Although the OIR procedure has been well established in detail, few studies to date have examined the effect of intravitreal injection using different-sized syringe needles at different time intervals after mouse pups returned to room air on this model. Initially, the significant reduction of NV and VO areas in the vehicle-controls of OIR drew our attention. We found that intravitreal injection performed using a 33 g-needle at 2 h after the pups returned to room air resulted in minimal NV and VO areas, causing a failure of OIR model. The results of ERG and OCT testing showed that 34 g-needle was more suitable than a 33 g-needle for intravitreal injection in the OIR model. We then investigated the effect of time interval after pups returned to room air on the OIR model. The results indicated that 8-24 h was a more suitable time for performing intravitreal injection. In conclusion, appropriate control of the effects of intravitreal injection on OIR requires attention to gauge of needle used, and the time interval after return of pups to room air.
Weight gain effects of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in people with HIV (PWH) have been sparsely studied.Participants were enrolled in the Copenhagen Comorbidity in HIV Infection (COCOMO) study. PWH receiving a backbone of emtricitabine, or lamivudine combined with abacavir, tenofovir disoproxil, or tenofovir alafenamide were analysed. Weight gain according to ART backbone and to the third drug was analysed using a multiple linear regression model. Non-ART risk factors were also determined using multiple linear regression.A total of 591 participants were included in the analysis. The majority were middle-aged, virally suppressed males with a mean BMI just above the normal range. Both tenofovir disoproxil/emtricitabine or lamivudine and abacavir /emtricitabine or lamivudine, but not tenofovir alafenamide /emtricitabine or lamivudine were associated with weight gain over two years (0.6 kg, p = 0.025; 1.0 kg, p = 0.005). The third drugs associated with weight increase were non-nucleoside reverse transcriptase inhibitors (NNRTI) (p = 0.035), dolutegravir (p = 0.008) and atazanavir (p = 0.040). Non-ART risk factors for gaining weight were low or normal BMI, age <40 years, underweight, inactivity or highly active at baseline.Tenofovir disoproxil and abacavir-based ART regimens were associated with a small weight gain. Third drug NNRTI, dolutegravir and atazanavir were associated with an increase in weight.
Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.

NUCYNTA™ should be administered with caution to patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA™ may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA™ should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression [see Overdosage (10.2)].
BACKGROUND: Early identification of patients at risk of nosocomial pneumonia enables the opportunity for preventative measures, which may improve survival and reduce costs. Therefore, this study aimed to externally validate an existing prediction model (issued by Croce et al.) to predict nosocomial pneumonia in patients admitted to US level-1 trauma centers.
METHODS: A retrospective cohort study including patients admitted to level-1 trauma centers and registered in the TQIP, a US nationwide trauma registry, admitted between 2013-2015 and 2017-2019. The main outcome was total nosocomial pneumonia for the first period and ventilator-associated pneumonia (VAP) for the second. Model discrimination and calibration were assessed before and after recalibration.
RESULTS: The study comprised 902,231 trauma patients (N2013-2015 ​= ​180,601; N2017-2019 ​= ​721,630), with a median age of 52 in both periods, 64-65 ​% male, and approximately 90 ​% sustaining blunt traumatic injury. The median Injury Severity Scores were 13 (2013-2015) versus 9 (2017-2019); median Glasgow Coma Scale scores were 15. Nosocomial pneumonia incidence was 4.4 ​%, VAP incidence was 0.7 ​%. The original model demonstrated good to excellent discrimination for both periods (c-statistic2013-2015 0.84, 95%CI 0.83-0.84; c-statistic2017-2019 0.92, 95%CI 0.91-0.92). After recalibration, discriminatory capacity and calibration for the lower predicted probabilities improved.
CONCLUSIONS: The Croce model can identify patients admitted to US level-1 trauma centers at risk of total nosocomial pneumonia and VAP. Implementing (modified) Croce models in route trauma clinical practice could guide judicious use of preventative measures and prescription of additional non-invasive preventative measures (e.g., increased monitoring, pulmonary physiotherapy) to decrease the occurrence of nosocomial pneumonia in at-risk patients.